# UBS Resumes Regeneron Coverage at Buy, Citing Dupixent Follow-Ons

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/32096
Published: 2026-10-14T21:50:04.000Z
Updated: 2026-10-14T21:50:04.000Z
Section: Business

> The bank sees potential value in follow-on treatments to Dupixent and the potential to expand the drug’s exclusivity.

UBS resumed coverage of Regeneron Pharmaceuticals with a Buy rating, citing potential value from follow-on treatments to Dupixent and the possibility of expanding the drug’s exclusivity.

Dupixent, also known as dupilumab, is Regeneron’s blockbuster treatment. UBS’s assessment is that the Street is not accounting for enough value from the drug’s follow-on development or its exclusivity potential.